Tauroursodeoxycholic Acid vs Ursodeoxycholic Acid: Which is better?

UDCA is the basic free ursodeoxycholic acid, which is naturally present in bile and is a classic choleretic drug that has been used clinically for many years. It has long been approved by the FDA for the treatment of primary biliary cholangitis (PBC).

Ursodeoxycholic acid (UDCA) is a hydrophilic, non-cytotoxic bile acid with anti-inflammatory, bile secretion-promoting, anti-apoptotic, and immunomodulatory effects.
Its mechanism involves promoting the excretion of endogenous bile acids and increasing the proportion of hydrophilic bile acids, thereby protecting hepatocytes and bile duct cells from damage by hydrophobic bile acids and improving liver function. Clinically, it is widely used for cholesterol gallstones, bile reflux gastritis, and cholestatic liver diseases (such as primary biliary cirrhosis).

In the treatment of gallstones, UDCA can reduce hepatic cholesterol secretion, increase cholesterol solubility, and lower the cholesterol saturation index of bile, effectively dissolving small stones.
Especially in obese patients undergoing rapid weight loss after bariatric surgery, it can significantly prevent the formation of gallstones and biliary sludge, reducing the risk of complications such as acute biliary pancreatitis. Furthermore, UDCA can protect hepatocytes and delay the progression of non-alcoholic fatty liver disease to steatohepatitis.

As a highly hydrophilic bile acid, tauroursodeoxycholic Acid Powdercan effectively cross the blood-brain barrier and has significant neuroprotective effects on the central nervous system and retina.
Studies have shown that in Parkinson's disease, Alzheimer's disease, and various retinopathy models, it slows down the degenerative changes of neurons and retinal cells through mechanisms such as inhibiting apoptosis, reducing inflammation, alleviating oxidative stress, inhibiting endoplasmic reticulum stress, and reducing angiogenesis.

UDCA has the potential to slow disease progression through multiple targets in neuroprotection.
In Parkinson's disease and Alzheimer's disease models, it can effectively cross the blood-brain barrier, restore mitochondrial function by stabilizing mitochondrial membrane potential and promoting ATP synthesis, reduce oxidative stress by scavenging reactive oxygen species, inhibit neuroinflammation by inhibiting pathways such as NF-κB, inhibit apoptosis, and enhance autophagy to clear toxic protein aggregates, thereby protecting neuronal integrity and improving motor and cognitive functions.

In terms of safety, multiple large-scale, multicenter clinical trials have shown that both TUDCA and UDCA have excellent tolerability and similar rates of adverse events. However, they differ slightly in their focus on improving specific clinical symptoms in patients.

In a double-blind, controlled trial of 199 patients with pneumococcal purpura (PBC), the proportion of patients taking UDCA who experienced increased itching or scratching was higher, while the TUDCA bulk powder treatment group showed more stable improvement in itching symptoms with no increase in such discomfort. Common gastrointestinal side effects were roughly equivalent for both treatments, but in certain populations, TUDCA tauroursodeoxycholic acid was less irritating to the gastrointestinal mucosa.

Which one is "better" depends entirely on your health needs and the purpose of your application. If you are dealing with a clear clinical case of cholestatic liver disease, UDCA, which is FDA-approved and has a very long history of clinical use, is usually the preferred standard treatment.

However, if you are looking for a supplement that can cross the blood-brain barrier, relieve cellular stress, provide neuroprotection, and is minimally converted into toxic lithocholic acid in daily liver care, then TUDCA, with its higher bioactivity and water solubility, is undoubtedly a more advanced and comprehensive choice.